Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

贝伐单抗 医学 伊立替康 奥沙利铂 化疗 结直肠癌 化疗方案 内科学 养生 外科 肿瘤科 临床终点 随机对照试验 癌症
作者
Jaafar Bennouna,Javier Sastre,Dirk Arnold,Pia Österlund,Richard Greil,Eric Van Cutsem,Roger von Moos,José María Viéitez,Olivier Bouché,Christophe Borg,Claus-Christoph Steffens,Vicente Alonso-Orduña,C. Schlichting,Irmarie Reyes‐Rivera,Belguendouz Bendahmane,Thierry André,Stefan Kubicka
出处
期刊:Lancet Oncology [Elsevier]
卷期号:14 (1): 29-37 被引量:1094
标识
DOI:10.1016/s1470-2045(12)70477-1
摘要

Background Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and bevacizumab-naive second-line metastatic colorectal cancer. We assessed continued use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment. Methods In an open-label, phase 3 study in 220 centres in Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, the Netherlands, Norway, Portugal, Saudi Arabia, Spain, Sweden, and Switzerland, patients (aged ≥18 years) with unresectable, histologically confirmed metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy were randomly assigned in a 1:1 ratio to second-line chemotherapy with or without bevacizumab 2·5 mg/kg per week equivalent (either 5 mg/kg every 2 weeks or 7·5 mg/kg every 3 weeks, intravenously). The choice between oxaliplatin-based or irinotecan-based second-line chemotherapy depended on the first-line regimen (switch of chemotherapy). A combination of a permuted block design and the Pocock and Simon minimisation algorithm was used for the randomisation. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00700102. Findings Between Feb 1, 2006, and June 9, 2010, 409 (50%) patients were assigned to bevacizumab plus chemotherapy and 411 (50%) to chemotherapy alone. Median follow-up was 11·1 months (IQR 6·4–15·6) in the bevacizumab plus chemotherapy group and 9·6 months (5·4–13·9) in the chemotherapy alone group. Median overall survival was 11·2 months (95% CI 10·4–12·2) for bevacizumab plus chemotherapy and 9·8 months (8·9–10·7) for chemotherapy alone (hazard ratio 0·81, 95% CI 0·69–0·94; unstratified log-rank test p=0·0062). Grade 3–5 bleeding or haemorrhage (eight [2%] vs one [<1%]), gastrointestinal perforation (seven [2%] vs three [<1%]), and venous thromboembolisms (19 [5%] vs 12 [3%]) were more common in the bevacizumab plus chemotherapy group than in the chemotherapy alone group. The most frequently reported grade 3–5 adverse events were neutropenia (65 [16%] in the bevacizumab and chemotherapy group vs 52 [13%] in the chemotherapy alone group), diarrhoea (40 [10%] vs 34 [8%], respectively), and asthenia (23 [6%] vs 17 [4%], respectively). Treatment-related deaths were reported for four patients in the bevacizumab plus chemotherapy group and three in the chemotherapy alone group. Interpretation Maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond disease progression has clinical benefits in patients with metastatic colorectal cancer. This approach is also being investigated in other tumour types, including metastatic breast and non-small cell lung cancers. Funding F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
陌路完成签到,获得积分10
1秒前
善学以致用应助leon采纳,获得30
1秒前
2秒前
斯文败类应助嘻嘻采纳,获得10
2秒前
科研通AI5应助小只bb采纳,获得30
2秒前
yyyy发布了新的文献求助10
2秒前
2023AKY完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
彭于晏应助惠惠采纳,获得10
5秒前
风魂剑主完成签到,获得积分10
6秒前
yryzst9899发布了新的文献求助10
6秒前
7秒前
飘逸小笼包完成签到,获得积分10
7秒前
科研小郑完成签到,获得积分10
7秒前
CipherSage应助熊boy采纳,获得10
7秒前
XXGG完成签到 ,获得积分10
8秒前
大个应助舒心赛凤采纳,获得10
8秒前
晨曦发布了新的文献求助10
9秒前
9秒前
ff0110完成签到,获得积分10
10秒前
星辰大海应助苹果萧采纳,获得10
10秒前
徐徐完成签到,获得积分10
10秒前
哈哈哈哈发布了新的文献求助10
11秒前
请叫我风吹麦浪应助yoon采纳,获得10
11秒前
认真的青柠完成签到,获得积分10
11秒前
bbanshan完成签到,获得积分10
11秒前
卫生纸发布了新的文献求助10
11秒前
11秒前
12秒前
奔奔完成签到,获得积分10
12秒前
脑洞疼应助李来仪采纳,获得10
13秒前
13秒前
13秒前
demonox发布了新的文献求助10
13秒前
jbhb发布了新的文献求助10
14秒前
14秒前
14秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527849
求助须知:如何正确求助?哪些是违规求助? 3107938
关于积分的说明 9287239
捐赠科研通 2805706
什么是DOI,文献DOI怎么找? 1540033
邀请新用户注册赠送积分活动 716893
科研通“疑难数据库(出版商)”最低求助积分说明 709794